Treatment of Clinically Involved Lymph Nodes

  • Arne Grün
Part of the Medical Radiology book series (MEDRAD)


Today long-term survival in patients present with lymphatic disease is not uncommon although treatment approaches for prostate cancer patients with pelvic nodal disease without further metastatic spread is highly individual as no clear evidence on the superiority of any approach exists. Practical aproaches can be extrapolated from studies on high-risk patients.


Overall Survival Prostate Cancer Patient Nodal Disease EORTC Trial AJCC Cancer Staging Manual 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Androgen deprivation therapy


Cancer-specific survival


Disease free survival


Disease-specific survival


External beam radiotherapy


Extensive pelvic lymph node dissection




Locally advanced prostate cancer


Lymph node


Progression-free survival


Overall survival


  1. Aus G, Nordenskjöld K, Robinson D (2003) Prognostic factors and survival in node-positive (N1) prostate cancer—a prospective study based on data from a swedish population-based cohort. Eur Urol 43:627–631PubMedCrossRefGoogle Scholar
  2. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–108PubMedCrossRefGoogle Scholar
  3. Bolla M, de Reijke TM, van Tienhoven G (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527PubMedCrossRefGoogle Scholar
  4. Bolla M, van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073PubMedCrossRefGoogle Scholar
  5. Boorjian SA, Thompson RH, Siddiqui S (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Urol 178:864–870CrossRefGoogle Scholar
  6. Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. a new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55:261–270PubMedCrossRefGoogle Scholar
  7. Gervasi LA, Mata J, Easley JD et al (1989) Prognostic significance of lymph node metastases in prostate cancer. J Urol 142:332–336PubMedGoogle Scholar
  8. Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897PubMedCrossRefGoogle Scholar
  9. Nguyen PL, Chen MH, Hoffman KE et al (2009) Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Biol Phys 74:104–109CrossRefGoogle Scholar
  10. Palapattu GS, Allaf ME, Trock BJ et al (2004) Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term follow-up. J Urol 172:1860–1864PubMedCrossRefGoogle Scholar
  11. Paul A, Ploussard G, Nicolaiew N et al (2009) Oncologic outcome after extraperitoneal laparoscopic radical prostataectomy: midterm follow-up of 1115 procedures. Eur Urol 57:267–272PubMedCrossRefGoogle Scholar
  12. Studer UE, Whelan P, Albrecht W et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891. J Clin Oncol 24:1868–1876PubMedCrossRefGoogle Scholar
  13. Tward JD, Kokeny KE, Shrieve DC (2013) Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol 3:234–240PubMedCrossRefGoogle Scholar
  14. Zagars G, Sands ME, Pollack A (1994) Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol 151:1330–1333PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department for Radiation Oncology and Cyberknife CenteCharité - University Medicine Berlin Campus Virchow-Clinic BerlinGermany

Personalised recommendations